Drug Type Biosimilar, Monoclonal antibody |
Synonyms Omalizumab Biosimilar (Curateq Biologics Pvt Ltd.), 奥马珠单抗生物类似药(Curateq Biologics Pvt Ltd.), BP 11 + [3] |
Target |
Action inhibitors |
Mechanism IgE inhibitors(Immunoglobulin E inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Chronic Urticaria | Phase 3 | India | 01 Aug 2024 | |
| Asthma | Phase 3 | India | 10 Nov 2023 |






